Nutriband Inc. (NTRBW) स्टॉक विश्लेषण

कंपनी का अवलोकन

Nutriband Inc. (NTRBW) is engaged in the development of a portfolio of transdermal pharmaceutical products within the United States, with its primary focus currently on AVERSA fentanyl, an abuse deterrent transdermal system designed for extended-release delivery. The company operates in the pharmaceutical sector, specifically within the sub-industry of transdermal drug delivery systems, though specific sector classifications and industry designations are not publicly disclosed in available data. The firm's current scale is characterized by a market capitalization that is not reported, with total annual revenue over the trailing twelve months standing at $2.28M and an employee count that remains unquantified in public filings. These valuation metrics, particularly the absence of a reported market cap alongside modest revenue figures, indicate that the company functions as a micro-cap entity with limited operational scale relative to established pharmaceutical peers, suggesting a high-risk profile typical of early-stage biotech or specialty drug developers.

वित्तीय स्वास्थ्य

Over the trailing twelve months, Nutriband Inc. reported a revenue of $2.28M, yet the net income figure stands at a significant loss of $-34,592,176, while EBITDA reflects an operational loss of $-9,029,840. The substantial disparity between the positive revenue of $2.28M and the massive negative net income reveals a cost structure where operating expenses, likely including significant R&D costs for AVERSA fentanyl and general administrative overhead, far exceed total sales revenue. The company's free cash flow is reported at $-2,588,350, indicating a continuous consumption of cash reserves that constrains financial flexibility and necessitates ongoing capital raises or asset liquidation to sustain operations. Margin analysis shows a gross margin of 33.5%, suggesting that the cost of goods sold for transdermal products is manageable, but the operating margin is reported at -1121.3% and the profit margin at 0.0%, highlighting severe operational inefficiencies or heavy fixed costs relative to sales volume. Regarding liquidity and leverage, the company holds $5.31M in cash against a debt obligation of $258,025, resulting in a debt-to-equity ratio of 3.42, which implies a highly leveraged balance sheet relative to its equity base. The current ratio stands at 7.53, indicating that the company possesses ample short-term assets to cover its short-term liabilities, suggesting strong immediate liquidity despite the overall net loss. Furthermore, the Return on Equity is -136.1% and the Return on Assets is -55.2%, metrics that collectively reveal that management's current strategies are not generating positive returns on capital invested and are instead eroding shareholder and asset value.

मूल्यांकन आकलन

The trailing P/E ratio and forward P/E ratio for Nutriband Inc. are both listed as N/A due to the company's negative earnings history, meaning standard earnings-based valuation models cannot be applied to assess the expected earnings trajectory. The price-to-book ratio is reported at 1.85, indicating that the market values the company's equity at 1.85 times its book value, which suggests a premium valuation over the net asset value often seen in companies with high growth potential or intangible assets like intellectual property. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also unavailable (N/A) because the negative earnings and lack of reported sales multiples prevent a direct comparison with profitable peers. The stock price has fluctuated between a 52-week high of $4.50 and a 52-week low of $0.80, and without a specific current price to calculate the exact percentage, the trading range indicates significant volatility within this $3.70 spread. The beta value is 1.93, which signifies that the stock's price volatility is approximately 93% higher than the broader market, exposing investors to substantial systemic risk during market downturns.

Growth & Income

Nutriband Inc. experienced a revenue growth rate of -46.4% year-over-year, while earnings growth is not applicable (N/A) due to the company's continued losses, implying that revenue contraction is occurring alongside negative profitability rather than a divergence between top-line and bottom-line performance. As the company does not pay dividends, the dividend yield and payout ratio are both N/A, indicating that all available cash flow is directed toward operational sustainability and research efforts rather than shareholder distributions. Since the firm is not a dividend payer, it is expected to reinvest any remaining operational cash or raised capital into the development of AVERSA fentanyl and other transdermal products rather than distributing income. The overall growth and income profile for Nutriband Inc. is characterized by revenue decline, negative cash generation, and a lack of current income returns, presenting a high-risk investment profile focused solely on potential future product approvals and commercialization.